41 results on '"Okamoto, Isamu"'
Search Results
2. Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors
3. Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers
4. Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib
5. Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non–small cell lung cancer
6. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors
7. Dynamic monitoring of plasma DAMP proteins during various anticancer agents in advanced lung cancer patients
8. NEUROD1 is highly expressed in extensive disease small cell lung cancer by promoting migration
9. Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database
10. NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration
11. Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry
12. Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy
13. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan
14. Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti–PD-1 therapy
15. Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer
16. Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)
17. Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies
18. Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients
19. Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non–small cell lung cancer
20. Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer
21. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements
22. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort
23. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer
24. CD44 variant–dependent regulation of redox balance in EGFR mutation–positive non–small cell lung cancer: A target for treatment
25. Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1
26. Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non–small cell lung cancer
27. Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study
28. Phase II trial of weekly nab-paclitaxel for previously treated advanced non–small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301
29. Successful treatment with alectinib after crizotinib-induced esophageal ulceration
30. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
31. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model
32. Bilateral ovarian metastasis of non-small cell lung cancer with ALK rearrangement
33. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer
34. Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer
35. Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor
36. Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer
37. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation
38. Pemetrexed-induced edema of the eyelid
39. Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer
40. P-134 Expression of constitutively activated EGFRvIII in non-small cell lung cancer
41. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.